Pharmacologic Approaches to Improve Mitochondrial Function in AKI and CKD

Overview

Journal J Am Soc Nephrol

Specialty Nephrology

Date 2017 Aug 6

PMID 28778860

Citations 90

Authors

Hazel H Szeto

Affiliations

Soon will be listed here.

Abstract

AKI is associated with high morbidity and mortality, and it predisposes to the development and progression of CKD. Novel strategies that minimize AKI and halt the progression of CKD are urgently needed. Normal kidney function involves numerous different cell types, such as tubular epithelial cells, endothelial cells, and podocytes, working in concert. This delicate balance involves many energy-intensive processes. Fatty acids are the preferred energy substrates for the kidney, and defects in fatty acid oxidation and mitochondrial dysfunction are universally involved in diverse causes of AKI and CKD. This review provides an overview of ATP production and energy demands in the kidney and summarizes preclinical and clinical evidence of mitochondrial dysfunction in AKI and CKD. New therapeutic strategies targeting mitochondria protection and cellular bioenergetics are presented, with emphasis on those that have been evaluated in animal models of AKI and CKD. Targeting mitochondrial function and cellular bioenergetics upstream of cellular damage may offer advantages compared with targeting downstream inflammatory and fibrosis processes.

Citing Articles

Twist2 knockdown alleviates renal ischemia-reperfusion injury by maintaining mitochondrial function and enhancing mitophagy through Bnip3.

Zhang L, Ye J, Qiu C Hum Cell. 2025; 38(2):50.

PMID: 39918659 DOI: 10.1007/s13577-025-01177-z.

Preventive Effects of Resistance Training on Hemodynamics and Kidney Mitochondrial Bioenergetic Function in Ovariectomized Rats.

Queiroz A, Garcia C, Silva J, Cavalini D, Alexandrino A, Cunha A Int J Mol Sci. 2025; 26(1.

PMID: 39796122 PMC: 11720031. DOI: 10.3390/ijms26010266.

Tubular MYDGF Slows Progression of Chronic Kidney Disease by Maintaining Mitochondrial Homeostasis.

Liu X, Zhang Y, Wang Y, Yang Y, Qiao Z, Zhan P Adv Sci (Weinh). 2024; 12(3):e2409756.

PMID: 39587987 PMC: 11744703. DOI: 10.1002/advs.202409756.

Mitochondrial destabilization in tendinopathy and potential therapeutic strategies.

Cheng L, Zheng Q, Qiu K, Ker D, Chen X, Yin Z J Orthop Translat. 2024; 49:49-61.

PMID: 39430132 PMC: 11488423. DOI: 10.1016/j.jot.2024.09.003.

Exploring the role and therapeutic potential of lipid metabolism in acute kidney injury.

Zhang X, Wu W, Li Y, Peng Z Ren Fail. 2024; 46(2):2403652.

PMID: 39319697 PMC: 11425701. DOI: 10.1080/0886022X.2024.2403652.

References

Siegel N, Avison M, REILLY H, Alger J, Shulman R . Enhanced recovery of renal ATP with postischemic infusion of ATP-MgCl2 determined by 31P-NMR. Am J Physiol. 1983; 245(4):F530-4. DOI: 10.1152/ajprenal.1983.245.4.F530. View

Mount P, Power D . Balancing the energy equation for healthy kidneys. J Pathol. 2015; 237(4):407-10. DOI: 10.1002/path.4600. View

Birk A, Chao W, Liu S, Soong Y, Szeto H . Disruption of cytochrome c heme coordination is responsible for mitochondrial injury during ischemia. Biochim Biophys Acta. 2015; 1847(10):1075-84. PMC: 4547887. DOI: 10.1016/j.bbabio.2015.06.006. View

Park C, Zhang Y, Zhang X, Wu J, Chen L, Cha D . PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int. 2006; 69(9):1511-7. DOI: 10.1038/sj.ki.5000209. View

Szeto H, Liu S, Soong Y, Wu D, Darrah S, Cheng F . Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol. 2011; 22(6):1041-52. PMC: 3103724. DOI: 10.1681/ASN.2010080808. View

Kouroumichakis I, Papanas N, Zarogoulidis P, Liakopoulos V, Maltezos E, Mikhailidis D . Fibrates: therapeutic potential for diabetic nephropathy?. Eur J Intern Med. 2012; 23(4):309-16. DOI: 10.1016/j.ejim.2011.12.007. View

Wijermars L, Schaapherder A, de Vries D, Verschuren L, Wust R, Kostidis S . Defective postreperfusion metabolic recovery directly associates with incident delayed graft function. Kidney Int. 2016; 90(1):181-91. DOI: 10.1016/j.kint.2016.02.034. View

Inker L, Astor B, Fox C, Isakova T, Lash J, Peralta C . KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014; 63(5):713-35. DOI: 10.1053/j.ajkd.2014.01.416. View

Eirin A, Ebrahimi B, Zhang X, Zhu X, Woollard J, He Q . Mitochondrial protection restores renal function in swine atherosclerotic renovascular disease. Cardiovasc Res. 2014; 103(4):461-72. PMC: 4155472. DOI: 10.1093/cvr/cvu157. View

10.

Xiao L, Xu X, Zhang F, Wang M, Xu Y, Tang D . The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2/PINK1. Redox Biol. 2016; 11:297-311. PMC: 5196243. DOI: 10.1016/j.redox.2016.12.022. View

11.

Kagan V, Tyurin V, Jiang J, Tyurina Y, Ritov V, Amoscato A . Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat Chem Biol. 2006; 1(4):223-32. DOI: 10.1038/nchembio727. View

12.

Tran M, Tam D, Bardia A, Bhasin M, Rowe G, Kher A . PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest. 2011; 121(10):4003-14. PMC: 3195479. DOI: 10.1172/JCI58662. View

13.

Mizuguchi Y, Chen J, Seshan S, Poppas D, Szeto H, Felsen D . A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstruction. Am J Physiol Renal Physiol. 2008; 295(5):F1545-53. PMC: 2584902. DOI: 10.1152/ajprenal.00395.2007. View

14.

Szeto H, Liu S, Soong Y, Alam N, Prusky G, Seshan S . Protection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury. Kidney Int. 2016; 90(5):997-1011. DOI: 10.1016/j.kint.2016.06.013. View

15.

Decleves A, Zolkipli Z, Satriano J, Wang L, Nakayama T, Rogac M . Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury. Kidney Int. 2013; 85(3):611-23. PMC: 4244908. DOI: 10.1038/ki.2013.462. View

16.

Whitaker R, Corum D, Beeson C, Schnellmann R . Mitochondrial Biogenesis as a Pharmacological Target: A New Approach to Acute and Chronic Diseases. Annu Rev Pharmacol Toxicol. 2015; 56:229-49. DOI: 10.1146/annurev-pharmtox-010715-103155. View

17.

Plotnikov E, Chupyrkina A, Jankauskas S, Pevzner I, Silachev D, Skulachev V . Mechanisms of nephroprotective effect of mitochondria-targeted antioxidants under rhabdomyolysis and ischemia/reperfusion. Biochim Biophys Acta. 2010; 1812(1):77-86. DOI: 10.1016/j.bbadis.2010.09.008. View

18.

Reily C, Mitchell T, Chacko B, Benavides G, Murphy M, Darley-Usmar V . Mitochondrially targeted compounds and their impact on cellular bioenergetics. Redox Biol. 2013; 1(1):86-93. PMC: 3647698. DOI: 10.1016/j.redox.2012.11.009. View

19.

Kang H, Ahn S, Choi P, Ko Y, Han S, Chinga F . Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2014; 21(1):37-46. PMC: 4444078. DOI: 10.1038/nm.3762. View

20.

Suzuki T, Yamaguchi H, Kikusato M, Matsuhashi T, Matsuo A, Sato T . Mitochonic Acid 5 (MA-5), a Derivative of the Plant Hormone Indole-3-Acetic Acid, Improves Survival of Fibroblasts from Patients with Mitochondrial Diseases. Tohoku J Exp Med. 2015; 236(3):225-32. DOI: 10.1620/tjem.236.225. View